Ziftomenib (KOMET-007/ NCT05735184) is being investigated to assess its safety, tolerability, and preliminary antileukemic activity in combination with venetoclax and azacitidine (ven/aza), ven, and 7 + 3 for two different molecularly defined AML subgroups: NPM1-m and KMT2Ar in the relapsed/refractory setting. The gene discussed is NPM1; the disease is acute myeloid leukemia.